Corcept Therapeutics CORT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $164.9M+4.9% | $202.13M+11.1% | $207.64M+13.7% | $194.43M+18.7% | $157.21M+7.1% | ||
| $2.88M+20.0% | $2.55M-13.9% | $4.6M+60.3% | $3.43M+36.0% | $2.4M-5.2% | ||
| $66.27M+9.1% | $64.86M-7.7% | $68.85M+16.0% | $60.47M+2.9% | $60.74M+3.8% | ||
| $145.36M+60.3% | $130.24M+56.2% | $123.98M+68.1% | $103.85M+55.2% | $90.66M+61.1% | ||
| $214.5M+39.5% | $197.64M+26.2% | $197.42M+45.2% | $167.76M+30.9% | $153.8M+31.1% | ||
| -$49.6M-1,552% | $4.49M-82.2% | $10.22M-78.1% | $26.68M-25.1% | $3.42M-88.4% | ||
| -30.1%-32.3pp | 2.2%-11.7pp | 4.9%-20.6pp | 13.7%-8.0pp | 2.2%-17.9pp | ||
| $4.89M-21.2% | $5.42M-19.0% | $5.02M-20.8% | $5.02M-16.4% | $6.2M+12.9% | ||
| -$44.72M-565% | $9.91M-69.0% | $15.24M-71.2% | $31.69M-23.8% | $9.62M-72.5% | ||
| -$12.95M-18.5% | -$14.38M-1,284% | -$4.43M-177% | -$3.46M-157% | -$10.93M-251% | ||
| -$31.76M-255% | $24.29M-21.0% | $19.67M-58.3% | $35.15M-1.0% | $20.55M-26.0% | ||
| -19.3%-32.3pp | 12%-4.9pp | 9.5%-16.4pp | 18.1%-3.6pp | 13.1%-5.8pp | ||
| -$0.30-276% | $0.20-20.0% | $0.16-61.0% | $0.29-9.4% | $0.17-32.0% | ||
| -$49M-1,364% | $4.78M-81.3% | $10.51M-77.6% | $26.78M-24.9% | $3.88M-86.9% | ||
| -29.7%-32.2pp | 2.4%-11.7pp | 5.1%-20.6pp | 13.8%-8.0pp | 2.5%-17.7pp | ||
| -$49.6M-1,552% | $4.49M-82.2% | $10.22M-78.1% | $26.68M-25.1% | $3.42M-88.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Corcept Therapeutics's revenue?
- Corcept Therapeutics (CORT) generated $769.1M in revenue over the trailing twelve months, up 12.2% year over year.
- Is Corcept Therapeutics profitable?
- Corcept Therapeutics reported $47.3M in net income over the trailing twelve months, a 6.2% net margin.
- What are Corcept Therapeutics's profit margins?
- Gross margin is 98.3% and operating margin is -1.1%, with a 6.2% net margin.
- What is Corcept Therapeutics's earnings per share?
- Corcept Therapeutics's diluted EPS over the trailing twelve months is $0.35.
- Where does Corcept Therapeutics's income statement data come from?
- Every line is extracted from Corcept Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
